

PATENT

Attorney Docket No.: 0832-0082 DI1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re: Patent application of :
Hui Zhang, et al :
Serial No.: Not Yet Assigned : Group Art Unit:
: Not Yet Assigned
Filed: Herewith : Examiner:
: Not Yet Assigned
For: MULTIMERIZATION OF HIV-1 VIF
PROTEIN AS A THERAPEUTIC TARGET

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Pursuant to 37 C.F.R. §1.56 and in accordance with 37 C.F.R. §§1.97-1.98, submitted herewith are copies of the references listed below and on the accompanying Form PTO-1449.

CERTIFICATE OF MAILING UNDER 37 C.F.R. 1.10	
EXPRESS MAIL Mailing Label Number: <u>EV320478711US</u>	
Date of Deposit: <u>9/17/03</u>	
I hereby certify that this correspondence, along with any paper referred to as being attached or enclosed, and/or fee, is being deposited with the United States Postal Service, "EXPRESS MAIL-POST OFFICE TO ADDRESSEE" service under 37 CFR 1.10, on the date indicated above, and addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.	
Signature of person mailing page: <u>Jackie Williams</u>	
Type or print name of person	

This statement is being filed concurrently with the filing of the above-referenced application. No fee should be due for the filing of this statement.

The Examiner is respectfully requested to review the references identified herein and make them of record in the instant application as required by M.P.E.P. §609.

The references listed in this IDS comprise the most pertinent prior art known to applicant and its attorneys as of the date hereof. This IDS should not be construed as a representation that the cited references are material or that no better art exists.

It is requested that the Examiner initial the enclosed duplicate substitute PTO Form 1449, and return one copy to Applicants' undersigned representative with the next action.

Respectfully submitted,
HUI ZHANG, et al.



DANIEL A. MONACO
Registration No. 30,480
DRINKER BIDDLE & REATH LLP.
One Logan Square
18th and Cherry Streets
Philadelphia, PA 19103-6996
(215) 988-3312 - phone
(215) 988-2757 - Fax

Attorney for the Applicants

SUBSTITUTE FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. 08321-0082 DI1	SERIAL NO. Not Yet Assigned
INFORMATION DISCLOSURE CITATION			
APPLICANT: Hui Zhang, et al.			
FILING DATE Concurrently Herewith		GROUP Not Yet Assigned	

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE (IF APPROPRIATE)
	AA						
	AB						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NO.	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES	NO
	AC	02/081504 A3	17/10/02	WIPO				
	AD	0959136A1	24/11/99	EP				
	AE	0330359A2	30/08/89	EP				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

AF	CHOPPIN J ET AL.: "Analysis of Physical Interactions between Peptides and HLA Molecules and Application to the Detection of Human Immunodeficiency Virus 1 Antigenic Peptides", JOURNAL OF EXPERIMENTAL MEDICINE, Vol. 172, September 1990, pages 889-899
AG	FRIEDA ET AL.: "Peptides Derived from HIV-1 Vif: A Non-substrate Based Novel Type of HIV-1 Protease Inhibitors", JOURNAL OF MOLECULAR BIOLOGY, Vol. 287, 1999, pages 93-101
AH	JIN X ET AL.: "Identification of Subdominant Cytotoxic T Lymphocyte Epitopes Encoded by Autologous HIV Type 1 Sequences, Using Dendritic Cell Stimulation and Computer-Driven Algorithm" AIDS RESEARCH AND HUMAN RETROVIRUSES, Vol. 16, No. 1, January 2000
AI	YANG S ET AL.: "The Multimerization of Human Immunodeficiency Virus Type I Vif Protein", THE JOURNAL OF BIOLOGICAL CHEMISTRY, Vol. 276, No. 7, 8 November 2000, pages 4889-4893
AJ	ZHANG, HUI ET AL.: "Human Immunodeficiency Virus Type 1 Vif Protein Is an Integral Component of an mRNP Complex of Viral RNA and Could Be Involved in the Viral RNA Folding and Packaging Process", JOURNAL OF VIROLOGY, Sept. 2000, p. 8252-8261
AK	GUY ET AL.: "A specific inhibitor of cysteine proteases impairs a Vif-dependent modification of human immunodeficiency virus type 1 Env protein", JOURNAL OF VIROLOGY, Vol. 65, No. 3 (March 1991), pp. 1325-31 (abstract only)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SUBSTITUTE FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. 8321-82-DI1	SERIAL NO. Not Yet Assigned
INFORMATION DISCLOSURE CITATION		APPLICANT: Hui Zhang, et al.	
		FILING DATE Concurrently Herewith	GROUP Not Yet Assigned

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE (IF APPROPRIATE)
	BA						
	BB						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NO.	DATE	COUNTRY	CLASS	SUBCLASS	<u>TRANSLATION</u> YES	NO
	BC							
	BD							
	BE							

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

BF	YANG, ET AL.: "Mitogen-activated Protein Kinase Phosphorylates and Regulates the HIV-1 Vif Protein", <i>The Journal of Biological Chemistry</i> , Vol. 273, No. 45, Issue of November 6, 1998 pp. 29879-29887.
BG	SIMON, JAMES H.M., ET AL.: "Mutational Analysis of the Human Immunodeficiency Virus Type 1 Vif Protein", <i>Journal of Virology</i> , Vol. 73, No. 4, Apr. 1999, pp. 2675-2681
BH	HUVENT, ISABELLE, ET AL.: "Interaction and co-encapsidation of human immunodeficiency virus type 1 Gag and Vif recombinant proteins" <i>Journal of General Virology</i> , Vol. 79, pp. 1069-1081 (1998)
BI	GONCALVES, JOAO, ET AL.: "Biological Activity of Human Immunodeficiency Virus Type 1 Vif Requires Membrane Targeting by C-Terminal Basic Domains", <i>Journal of Virology</i> , Vol. 69, No. 11, Nov. 1995, pp. 7196-7204
BJ	BOUYAC, MICHELE, ET AL.: "Human Immunodeficiency Virus Type 1 Vif Protein Binds to the Pr55 ^{Gag} Precursor", <i>Journal of Virology</i> , Vol. 71, No. 12, Dec. 1997, pp. 9358-9365

EXAMINER	DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.